Tracy Stokol ^* Gabrielle Nickerson Martha Shuman Nicole Belcher

• Cornell University, Ithaca, United States

In the published article, there was an error in Figure 1, Table 1, Table 2, Table 3 and Table 5 as should be CD1a. The authors discovered this error after publication of the article when the source of the antibody sent a notification stating that the antigen was not CD1c as originally indicated. The corrected Figure and Tables and their captions appear below.The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.Figure 1: Algorithm used to diagnose acute myeloid leukemia (AML) in the 25 dogs of this study. This diagnostic algorithm was based on the order in which tests were generally performed in our laboratory, i.e., morphologic assessment of blood, bone marrow, or body cavity fluid or tissue aspirates, followed by flow cytometric analysis (performed routinely twice a week), followed by cytochemical staining (performed as needed). After completion of all the tests, the results were reevaluated, and a diagnosis of AML was based on the combined data. The path used to diagnose each case (#) is also shown. More details on the criteria are provided in Table 1. Table 1: Criteria used to support myeloid lineage of leukemia in 25 dogs. Criteria Morphologic features of myeloid differentiation (16,17) Neutrophil differentiation (immature and mature neutrophils), monocytoid nuclei, magenta to purple cytoplasmic granules that frequently overlay the nuclei, light red to pink cytoplasmic granules within a light blue cytoplasm, or dysplasia in one or more hematopoietic cell lineages (e.g., giant band neutrophils, neutrophil hypersegmentation, bizarre monocytes, megaloblastic erythroblasts, fragmented or multiple Howell-jolly bodies, giant or abnormally granulated platelets, micromegakaryocytes) Flow cytometric markers of myeloid differentiation ( 16) Neutrophilic differentiation: antineutrophil antibody, monocytic differentiation: CD14, CD11d, or CD1a (the latter two with negative T cell markers), neutrophilic or monocytic differentiation: CD11b, CD11c, or CD4 (the latter with negative T cell markers), megakaryocytes: CD61 Cytochemical stains characteristic of myeloid differentiation (16,35) Neutrophils: CAE, MPx, SBB, monocytes: light to strong ALP (monoblasts, differentiating monocytes), diffuse light to chunky ANBE (differentiating monocytes, monoblasts), may be positive for MPx (weaker than neutrophils) or SBB (weaker than neutrophils)The tests used to define criteria were run sequentially (Figure 1), but the combined results were evaluated after completion of analysis to obtain a definitive diagnosis of AML.